Spots Global Cancer Trial Database for A Study of QBI-139 in Subjects With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of QBI-139 in Subjects With Advanced Solid Tumors
Official Title: Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients With Refractory Malignancies
Study ID: NCT00818831
Conditions
Interventions
Study Description
Brief Summary: The purposes of this trial are: * To evaluate the toxicity and tolerability of QBI-139 in patients with advanced refractory solid tumors. * To determine the maximum tolerated dose of QBI-139 in patients with advanced, refractory solid tumors. Patients will receive QBI-139 by IV infusion over at least one hour once weekly for three weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients receive escalating doses of QBI-139 until the maximum tolerated dose (MTD) is determined.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
